Avastin Injection, Solution
Product Images NDC 50242-061

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Avastin (NDC 50242-061). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Avastin 01)

This is a graph showing the duration of survival in months for two groups of patients. The groups are referred to as IFL + Placebo and IFL + Avastin, and the graph shows the number of patients at risk at different time intervals. However, without more context, it is difficult to draw any conclusions.*

FDA Label Image

Figure 2 (Avastin 02)

FDA Label Image

Figure 3 (Avastin 03)

FDA Label Image

Figure 4 (Avastin 04)

This is a chart displaying the Progression Free Survival rate of two treatments: Placebo + IFN-alfa and Avastin + IFN-affa. The rate is measured in months and ranges from 2 to 49 months for Placebo + IFN-alfa and 8 to 87 months for Avastin + IFN-alfa. The chart also indicates the number of patients who received each treatment (n=322 for Placebo + IFN-alfa and n=327 for Avastin + IFN-alfa).*

FDA Label Image

Figure 5 (Avastin 05)

This appears to be a table or graph displaying data on the number of patients at risk and the proportion of overall survival for a treatment group receiving chemotherapy alone versus chemotherapy plus a drug called Bev. However, the text obtained by is not readable and therefore a useful description cannot be generated.*

FDA Label Image

Figure 6 (Avastin 06)

FDA Label Image

Figure 7 (Avastin 07)

FDA Label Image

Figure 8 (Avastin 08)

FDA Label Image

Principal Display Panel (4 mL Vial Carton)

FDA Label Image

Avastin 09a

This appears to be a chart with data showing the number of patients at risk over time for two treatments, AVASTIN + atezolizumab and Sorafenib. The numbers seem to be split into different time points (months) with a percentage and a count of patients at risk for each. However, the text is not clear in some places, making the information difficult to interpret accurately.*

FDA Label Image

Principal Display Panel (4 mL Vial Carton)

This is a description of Avastin, a medication that comes in a single-dose vial for intravenous use. The NDC (National Drug Code) number is 50242-060-01 and it contains 100 mg/4 mL of bevacizumab. The vial should be discarded after use and it does not contain any preservatives. The lot number for this specific vial is 10213744.*

FDA Label Image

Avastin 11

NDC 50242-061-01 is the code for a single-dose vial of Avastin® (bevacizumab) injection which contains 400 mg/16mL with a strength of 25 mg/mL. This medication is used for intravenous use only and does not contain any preservatives. The product should be used once as it is a single-dose vial and any unused portion should be discarded. The information on the vial includes a unique product identification number (10213746) and the manufacturer's name (Ronly).*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.